BrainStorm Cell Therapeutics has decided to submit a BLA for NurOwn in ALS following an erratum to a phase 3 trial.
Merit Cudkowicz, MD, MSc
Advertisement
Articles by Merit Cudkowicz, MD, MSc
The director of the Healey & AMG Center for ALS spoke to the recent topline results of a phase 3 study of NurOwn in patients with the neuromuscular disease.
Advertisement
Latest Updated Articles
Merit Cudkowicz, MD, MSc: Assessing NurOwn in ALSPublished: January 4th 2021 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
M. Peter Marinkovich, MD, on Integrating Gene Therapy into Clinical Practice for Dermatologists
2
Quarter Century Update: Platform Approaches and Industry Investment
3
Quarter Century Update: How can Partnerships Between Academia, Biotech, and Pharma be Better Structured?
4
